...[Interpreted] Hello, I'm Manabe. Thank you for joining us today for the Daiichi Sankyo ENHERTU business briefing. We, at Daiichi Sankyo are committed to continuously create innovative drugs and provide medicines that meet diverse medical needs. And by doing so, our goal is to become one of the top 10 global companies in the oncology field by 2030. To, ENHERTU, an anticancer agent discovered and developed using our propriety DXd ADC technology is contributing to the treatment of breast cancer and many other cancer patients in the United States, Europe, Japan, Asia and Latin America as well as other countries and regions. Today, Ken Keller, Head of Oncology Business Unit, will explain expectations for further growth, including the maximization of the product value of ENHERTU through the acquisition and promotion of new indications. And in fiscal 2024, starting this April and beyond, so we will launch several DXd ADC products following ENHERTU and we are preparing for the start of sales promotion....